vs
Adaptive Biotechnologies Corp（ADPT）与艾伯维（ARGX）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Adaptive Biotechnologies Corp的34.5倍（$2.5B vs $71.7M）。艾伯维净利率更高（35.5% vs -18.9%，领先54.4%）。艾伯维同比增速更快（83.2% vs 51.0%）。艾伯维自由现金流更多（$322.4M vs $1.4M）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
ADPT vs ARGX — 直观对比
营收规模更大
ARGX
是对方的34.5倍
$71.7M
营收增速更快
ARGX
高出32.2%
51.0%
净利率更高
ARGX
高出54.4%
-18.9%
自由现金流更多
ARGX
多$321.0M
$1.4M
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $2.5B |
| 净利润 | $-13.6M | $877.2M |
| 毛利率 | 74.6% | 89.5% |
| 营业利润率 | -17.8% | 28.9% |
| 净利率 | -18.9% | 35.5% |
| 营收同比 | 51.0% | 83.2% |
| 净利润同比 | 59.7% | 1.3% |
| 每股收益（稀释后） | $-0.08 | $13.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTARGX
| Q4 25 | $71.7M | $2.5B | ||
| Q3 25 | $94.0M | — | ||
| Q2 25 | $58.9M | $1.8B | ||
| Q1 25 | $52.4M | — | ||
| Q4 24 | $47.5M | $1.4B | ||
| Q3 24 | $46.4M | — | ||
| Q2 24 | $43.2M | $901.9M | ||
| Q1 24 | $41.9M | — |
净利润ADPTARGX
| Q4 25 | $-13.6M | $877.2M | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $-25.6M | $414.8M | ||
| Q1 25 | $-29.9M | — | ||
| Q4 24 | $-33.7M | $865.6M | ||
| Q3 24 | $-32.1M | — | ||
| Q2 24 | $-46.2M | $-32.5M | ||
| Q1 24 | $-47.5M | — |
毛利率ADPTARGX
| Q4 25 | 74.6% | 89.5% | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | 89.2% | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | 90.2% | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | 89.4% | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTARGX
| Q4 25 | -17.8% | 28.9% | ||
| Q3 25 | 10.9% | — | ||
| Q2 25 | -42.5% | 19.2% | ||
| Q1 25 | -56.4% | — | ||
| Q4 24 | -71.3% | 8.7% | ||
| Q3 24 | -70.3% | — | ||
| Q2 24 | -109.6% | -15.4% | ||
| Q1 24 | -116.5% | — |
净利率ADPTARGX
| Q4 25 | -18.9% | 35.5% | ||
| Q3 25 | 10.2% | — | ||
| Q2 25 | -43.5% | 23.4% | ||
| Q1 25 | -56.9% | — | ||
| Q4 24 | -71.0% | 64.1% | ||
| Q3 24 | -69.1% | — | ||
| Q2 24 | -107.0% | -3.6% | ||
| Q1 24 | -113.5% | — |
每股收益（稀释后）ADPTARGX
| Q4 25 | $-0.08 | $13.25 | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.17 | $6.32 | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.22 | $13.33 | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.31 | $-0.55 | ||
| Q1 24 | $-0.33 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $3.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $218.8M | $7.3B |
| 总资产 | $512.7M | $8.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADPTARGX
| Q4 25 | $70.5M | $3.5B | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | $43.2M | $2.1B | ||
| Q1 25 | $50.6M | — | ||
| Q4 24 | $47.9M | $1.5B | ||
| Q3 24 | $38.1M | — | ||
| Q2 24 | $59.8M | $1.4B | ||
| Q1 24 | $71.2M | — |
总债务ADPTARGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | — |
股东权益ADPTARGX
| Q4 25 | $218.8M | $7.3B | ||
| Q3 25 | $204.4M | — | ||
| Q2 25 | $179.7M | $6.1B | ||
| Q1 25 | $190.4M | — | ||
| Q4 24 | $202.7M | $5.5B | ||
| Q3 24 | $223.8M | — | ||
| Q2 24 | $241.6M | $4.3B | ||
| Q1 24 | $274.9M | — |
总资产ADPTARGX
| Q4 25 | $512.7M | $8.7B | ||
| Q3 25 | $490.6M | — | ||
| Q2 25 | $496.6M | $7.2B | ||
| Q1 25 | $510.9M | — | ||
| Q4 24 | $539.4M | $6.2B | ||
| Q3 24 | $558.5M | — | ||
| Q2 24 | $584.9M | $4.8B | ||
| Q1 24 | $620.3M | — |
负债/权益比ADPTARGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $323.3M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | $322.4M |
| 自由现金流率自由现金流/营收 | 2.0% | 13.0% |
| 资本支出强度资本支出/营收 | 0.9% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.37× |
| 过去12个月自由现金流最近4个季度 | $-48.9M | $594.5M |
8季度趋势，按日历期对齐
经营现金流ADPTARGX
| Q4 25 | $2.1M | $323.3M | ||
| Q3 25 | $-7.1M | — | ||
| Q2 25 | $-12.4M | $361.8M | ||
| Q1 25 | $-28.5M | — | ||
| Q4 24 | $-12.5M | $41.9M | ||
| Q3 24 | $-27.1M | — | ||
| Q2 24 | $-17.3M | $-124.7M | ||
| Q1 24 | $-38.4M | — |
自由现金流ADPTARGX
| Q4 25 | $1.4M | $322.4M | ||
| Q3 25 | $-7.5M | — | ||
| Q2 25 | $-13.1M | $356.6M | ||
| Q1 25 | $-29.7M | — | ||
| Q4 24 | $-12.6M | $40.9M | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-19.0M | $-125.5M | ||
| Q1 24 | $-39.9M | — |
自由现金流率ADPTARGX
| Q4 25 | 2.0% | 13.0% | ||
| Q3 25 | -8.0% | — | ||
| Q2 25 | -22.2% | 20.1% | ||
| Q1 25 | -56.7% | — | ||
| Q4 24 | -26.5% | 3.0% | ||
| Q3 24 | -59.0% | — | ||
| Q2 24 | -44.1% | -13.9% | ||
| Q1 24 | -95.2% | — |
资本支出强度ADPTARGX
| Q4 25 | 0.9% | 0.0% | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 1.1% | 0.3% | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 4.0% | 0.1% | ||
| Q1 24 | 3.6% | — |
现金转化率ADPTARGX
| Q4 25 | — | 0.37× | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
ARGX
暂无分部数据
